Efficacy evaluation and side effects of cimepilimab

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor that belongs to the PD-1 inhibitor category and is widely used in the treatment of advanced non-small cell lung cancer, cutaneous squamous cell carcinoma and basal cell carcinoma and other cancer types. Its main mechanism is to restore the anti-tumor activity of T cells by blocking the binding of programmed cell death protein 1 (PD-1) and its ligand PD-L1, thereby improving the immune system's ability to recognize and attack tumors. This mechanism makes cimepilimab an important new therapeutic modality in cancer treatment.

The efficacy evaluation of cimipilimab is mainly based on the patient's progression-free survival (PFS), overall survival (OS) and tumor response rate. In practical applications, the efficacy of cimepilimab is often manifested in the delay of disease progression and tumor shrinkage in some patients, especially in patients who are ineffective or resistant to traditional treatment options such as chemotherapy and radiotherapy. Cimepilimab has shown good efficacy in promoting the restoration of function of the body's immune system and enhancing anti-tumor response. Compared with traditional treatments, cimepilimab provides a new treatment option, especially in patients with locally advanced or metastatic tumors that cannot be controlled by surgery or radiotherapy.

However, although cimepilimab offers new hope in cancer treatment, side effects are an important concern. Similar to other immune checkpoint inhibitors, most of the side effects of cimepilimab are due to overactivation of the immune system. While the immune system is restoring its attack function, it may mistakenly attack normal tissues, leading to immune-related adverse reactions. Common side effects include fatigue, decreased appetite, rash, difficulty breathing, etc. More serious side effects usually involve immune-mediated inflammatory reactions, which may affect multiple organs such as the lungs, liver, intestines, and endocrine system.

Reference materials:https://www.libtayohcp.com/